Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function

Authors: Chang-Chiang Chen, Hendra Susanto, Wen-Han Chuang, Ta-Yu Liu, Arivajiagane Arundhathi, Chih-Hong Wang

Published in: Cardiovascular Diabetology | Issue 1/2017

Login to get access

Excerpt

After publication of the original article [1], it came to the authors’ attention that a contributor to the study, Arivajiagane Arundhathi, had been inadvertently omitted from the author list. Her affiliation, Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, was also omitted. …
Literature
1.
Metadata
Title
Erratum to: Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function
Authors
Chang-Chiang Chen
Hendra Susanto
Wen-Han Chuang
Ta-Yu Liu
Arivajiagane Arundhathi
Chih-Hong Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0538-2

Other articles of this Issue 1/2017

Cardiovascular Diabetology 1/2017 Go to the issue

Review

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Original investigation

Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings

Original investigation

Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis

Original investigation

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Original investigation

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

Original investigation

Impact of renal function on the underlying pathophysiology of coronary plaque composition in patients with type 2 diabetes mellitus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits